Estimating SARS-CoV-2 Seroprevalence in the U.S. from Convenience Samples

Seroprevalence ranged from 1% to 23% in 4 cross-sectional samples tested at commercial laboratories between July 27 and September 24, 2020.

SARS-CoV-2 seroprevalence has been reported in specific U.S. populations and regions, but an extensive nationwide study has not been conducted. Building on a previous more-limited report, the CDC has published a large seroprevalence study assessing rates in all 50 states, Puerto Rico, and the District of Columbia.

During four collection periods between July 27 and September 24, a total of 177,919 samples of residual serum from two large commercial reference laboratories were tested for SARS-CoV-2 antibodies. Overall, 58% of samples were from women, 27% were from people aged ≥65, and 15% were from nonmetropolitan areas. While seroprevalence varied from <1% to 23%, in 42 of 49 jurisdictions with adequate samples, seroprevalence was <10%. New Y…

Reviewing Author

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Daniel Kaul, MD

Disclosures

Grant/Research SupportNobelpharma; Pfizer

Leadership Positions in Professional SocietiesAmerican Society of Transplantation (Program Committee)

Estimating SARS-CoV-2 Seroprevalence in the U.S. from Convenience Samples

Topics

Reviewing Author